GlassScriptPhysician profile
Joshua Rosenberg
NPI 1699906735
$60,943.04
in general payments reported to CMS, 2019-2025
7 companies · $8,434 in 2025
The $8,434 reported for 2025 was more than what 97% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $61.11 · 2021: $20.00 · 2022: $351 · 2023: $27K · 2024: $24K · 2025: $8,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Travel and Lodging: $5,955 · Food and Beverage: $4,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,600.00 |
| Consulting Fee | $12,400.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,500.00 |
| Travel and Lodging | $5,955.34 |
| Food and Beverage | $4,117.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $60,331.20 | 2019-2025 | Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Connector |
| Depuy Synthes Sales INC. | $245.62 | 2023-2024 | Trumatch |
| La Jolla Pharmaceutical Company | $157.22 | 2023 | Xerava, Xacduro |
| Kls-Martin L.P. | $127.89 | 2023-2024 | |
| Optinose US, INC. | $36.47 | 2020 | |
| Paratek Pharmaceuticals, INC. | $24.64 | 2020 | |
| Genzyme Corporation | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.